About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

6.000 +0.850 (+16.50%)
Official Closing Price Updated: 8:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 Next >
News headline image
CEL-SCI Reports Fiscal 2025 Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $10 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $10 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Combination of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
From CEL-SCI Corporation
Via Business Wire
News headline image
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
From CEL-SCI Corporation
Via Business Wire
News headline image
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Closing of $5 Million Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $5 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.